Item 7.01. Regulation FD Disclosure.

On May 18, 2021, Sarepta Therapeutics, Inc. (the "Company") issued a press release and conducted an investor webcast presenting 12-week expression and safety results from the first 11 participants enrolled in Study SRP-9001-103, the Company's investigational gene therapy for the treatment of Duchenne muscular dystrophy. Copies of the press release and the presentation are being furnished as Exhibits 99.1 and 99.2, respectively.

The information in this report, furnished pursuant to Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits



Exhibit No.   Description
   99.1         Press Release dated May 18, 2021: Sarepta Therapeutics'
              Investigational Gene Therapy for the Treatment of Duchenne Muscular
              Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent
              Safety Profile Using Sarepta's Commercial Process Material
   99.2         Presentation dated May 18, 2021: Clinical Update: Micro-dystrophin
              Gene Therapy Study SRP-9001-103: 12-Week Expression and Safety Data
              Using Commercially Representative Material
    104       The cover page from this Current Report on Form 8-K of Sarepta
              Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit
              101




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses